Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

101. Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy

Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy '); } else { document.write(' '); } ACE | Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Search > > Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy - Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Rifaximin 550 mg tablet as add (...) -on therapy to lactulose for reducing recurrent episodes of overt hepatic encephalopathy. Subsidy status Rifaximin 550 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

102. Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C

Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C '); } else { document.write(' '); } ACE | Direct-acting antiviral agents for genotype 2 to 6 chronic hepatitis C Search > > Direct-acting antiviral agent for treating genotype 2 to 6 chronic hepatitis C - Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C First published on 2 January 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sofosbuvir 400 mg (...) /velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: 12 weeks' treatment of sofosbuvir/velpatasvir for patients with genotype 2 to 6 hepatitis C virus without cirrhosis or with compensated cirrhosis (Child

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

103. Association of MBOAT7-TMC4 rs641738 with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus: a case-control study and meta-analysis Full Text available with Trip Pro

Association of MBOAT7-TMC4 rs641738 with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus: a case-control study and meta-analysis Association of MBOAT7-TMC4 rs641738 with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus: a case-control study and meta-analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research (...) Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Association of MBOAT7-TMC4 rs641738 with the risk of hepatocellular carcinoma and persistent infection of hepatitis B virus: a case-control study and meta-analysis Peng Wang, Yu Zhou, Lu Li, Yajie Gong, Rong Zhong, Na Shen Peng

2019 Research Square

104. Hepatitis C. (Abstract)

Hepatitis C. Hepatitis C is a global health problem, and an estimated 71·1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23·7 cases per 100 000 population (95% uncertainty interval 21·3-28·7) in 2015, with an estimated 1·75 million new HCV infections diagnosed in 2015. Globally, the most common infections are with HCV genotypes 1 (44% of cases), 3 (25% of cases), and 4 (15% of cases). HCV transmission is most commonly associated (...) % of individuals with hepatitis C know their diagnosis, and only 15% of those with known hepatitis C have been treated. Increased diagnosis and linkage to care through universal access to affordable point-of-care diagnostics and pangenotypic direct-acting antiviral therapy is essential to achieve the WHO 2030 elimination targets.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 Lancet

105. Hepatitis A and E Virus Outbreaks in the Mediterranean Region 2006-2017: A Systematic Review Full Text available with Trip Pro

Hepatitis A and E Virus Outbreaks in the Mediterranean Region 2006-2017: A Systematic Review ACTA SCIENTIFIC MICROBIOLOGY (ISSN: 2581-3226) Volume 2 Issue 11 November 2019 Hepatitis A and E Virus Outbreaks in the Mediterranean Region 2006-2017: A Systematic Review Elena Charalambous*, Ioanna P Chatziprodromidou and Apostolos Vantarakis Department of Public Health, School of Medicine, University of Patras, Greece *Corresponding Author: Elena Charalambous, Department of Public Health, School (...) of Medicine, University of Patras, Greece. Research Article Received: August 21, 2019; Published: October 11, 2019 Abstract Keywords: Hepatitis Virus; Hepatitis A; Hepatitis E; Outbreak; Mediterranean Introduction The prevalence of viral hepatitis is high and remains a serious public health challenge throughout the world [1,2]. An outbreak is commonly defined as the occurrence of cases of specific disease in a community with a frequency clearly in excess to normal ex- pectancy [3].The number of cases

2019 Acta Scientific Microbiology

106. Options for national testing and surveillance for hepatitis E virus in the EU/EEA

Options for national testing and surveillance for hepatitis E virus in the EU/EEA TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance www.ecdc.europa.euECDC TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Cornelia Adlhoch and produced by Cornelia (...) on request. Representatives of the European Food Safety Authority (EFSA, Valentina Rizzi and Michaela Hempen) and the World Health Organization Regional Office for Europe (Antons Mozalevskis) were observers in this group and received documents for review. The work was supported by two service contracts No. ECD.7600 (HEV epidemiological support – P/2017/OCS/253) and No. ID 5132 (Hepatitis B, C, and E in the EU/EEA: monitoring and testing activities). The following staff were involved on the contractor’s

2019 European Centre for Disease Prevention and Control - Technical Guidance

107. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial Full Text available with Trip Pro

Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal (...) ); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group).According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100

2019 EvidenceUpdates

108. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement

Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Joseph Doyle, Michelle Raggatt, Monica Slavin, Sue‐Anne McLachlan, Simone I Strasser, Joseph J Sasadeusz, Jessica Howell, Krispin Hajkowicz, Harshal Nandurkar, Anna Johnston, Narin Bak and Alexander J Thompson Med J

2019 MJA Clinical Guidelines

109. The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Full Text available with Trip Pro

The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake (...) of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 × 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean

2019 EvidenceUpdates

110. Screening for hepatitis C

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

111. Hepatitis C: interventions for case-finding and linkage to care

Hepatitis C: interventions for case-finding and linkage to care Hepatitis C: interventions for case-finding and linkage to care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis C: interventions for case-finding and linkage to care An evidence review of what interventions are effective in increasing case-finding and linkage to care for hepatitis C-infected patients. Published 26 July 2019 From (...) need. It will help us if you say what assistive technology you use. Details This report summarises the evidence for interventions, to increase case-finding and linkage to care for hepatitis C-infected patients. It is intended to support commissioners and health and care providers, in making decisions on prioritisation of resources and the commissioning of services. It is part of the ongoing effort to eliminate hepatitis C virus ( Collection Explore the topic Is this page useful? Thank you for your

2019 Public Health England

112. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia Full Text available with Trip Pro

An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia Teshiwal Deress Yazie, Mekonnen Girma Tebeje Teshiwal Deress Yazie University of Gondar Corresponding Author ORCiD: https://orcid.org/0000-0002-1678-604X Mekonnen Girma Tebeje University of Gondar DOI: License

2019 Research Square

113. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Full Text available with Trip Pro

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update

2019 Annals of Internal Medicine

114. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. (Abstract)

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) , -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.Lack of lipid, fibrosis, or HCC surveillance data.In a nationwide viral hepatitis cohort, lipophilic statins were associated with significantly reduced HCC incidence

2019 Annals of Internal Medicine

115. Comparison of the outcome of radiofrequency ablation or hepatic resection between solitary hepatocellular carcinoma and oligonodular hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis Full Text available with Trip Pro

Comparison of the outcome of radiofrequency ablation or hepatic resection between solitary hepatocellular carcinoma and oligonodular hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis Comparison of the outcome of radiofrequency ablation or hepatic resection between solitary hepatocellular carcinoma and oligonodular hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis | Adhikari | International Surgery Journal User Username (...) Password Remember me Journal Content Search Search Scope Browse Font Size Information Notifications Article Tools Email this article (Login required) > > DOI: Comparison of the outcome of radiofrequency ablation or hepatic resection between solitary hepatocellular carcinoma and oligonodular hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis Rajeev Adhikari, Tianfu Wen, Parvani Shrestha, Pooja Adhikari Abstract There are more literatures on the comparison

2019 International Surgery Journal

116. Acupuncture for chronic hepatitis B. Full Text available with Trip Pro

Acupuncture for chronic hepatitis B. Chronic hepatitis B is a liver disease associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming to reduce the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, as well as to improve health-related quality of life. Acupuncture is being used to decrease discomfort and improve immune function in people with chronic hepatitis B. However (...) , the benefits and harms of acupuncture still need to be established in a rigorous way.To assess the benefits and harms of acupuncture versus no intervention or sham acupuncture in people with chronic hepatitis B.We undertook electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded, Conference Proceedings Citation Index - Science, China National Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), Wanfang Data

2019 Cochrane

117. Daratumumab (Darzalex): risk of reactivation of hepatitis B virus

Daratumumab (Darzalex): risk of reactivation of hepatitis B virus Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab (...) . Published 19 August 2019 From: Therapeutic area: , , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with daratumumab, including several fatal cases worldwide screen all patients for hepatitis B virus before initiation of daratumumab; patients with unknown serology who are already on treatment should also be screened monitor patients with positive serology for clinical and laboratory signs of hepatitis B reactivation during treatment

2019 MHRA Drug Safety Update

118. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates

2019 Clinical Correlations

119. Host genetic factors associated with hepatitis B virus infection and progression to chronic disease: A systematic review and Meta analysis Full Text available with Trip Pro

Host genetic factors associated with hepatitis B virus infection and progression to chronic disease: A systematic review and Meta analysis Host genetic factors associated with hepatitis B virus infection and progression to chronic disease: A systematic review and Meta analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Host genetic factors associated with hepatitis B virus infection and progression to chronic disease: A systematic review and Meta analysis Hussein Mukasa Kafeero, Dorothy Ndagire Ndagire, Hasifah Nanyingi Nanyingi, Hakim Sendagire Sendagire Hussein Mukasa Kafeero Islamic University

2019 Research Square

120. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia Full Text available with Trip Pro

An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting (...) of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia Teshiwal Yazie, Mekonnen Girma Teshiwal Yazie University of Gondar Corresponding Author ORCiD: https://orcid.org/0000-0002-1678-604X Mekonnen Girma University of Gondar DOI: License: This work is licensed under

2019 Research Square